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Aim. To test the potential role of PPARγ in the endocrine abdominal tissue dysfunction induced by feeding normal rats with a
fructose rich diet (FRD) during three weeks. Methodology. Adult normal male rats received a standard commercial diet (CD) or
FRD, (10% in drinking water) without or with pioglitazone (PIO) (i.p. 0.25mg/Kg BW/day; CD-PIO and FRD-PIO). Thereafter,
we measured circulating metabolic, endocrine, and oxidative stress (OS) markers, abdominal adipose tissue (AAT) mass, leptin
(LEP) and plasminogen activator inhibitor-1 (PAI-1) tissue content/expression, and leptin release by isolated adipocytes incubated
with diﬀerent concentrations of insulin. Results. Plasma glucose, insulin, triglyceride, TBARS, LEP, and PAI-1 levels were higher in
FRD rats; PIO coadministration fully prevented all these increments. AAT adipocytes from FRD rats were larger, secreted a higher
amount of LEP, and displayed decreased sensitivity to insulin stimulation; these eﬀects were significantly ameliorated by PIO.
Whereas AAT LEP and PAI-1 (mRNA) concentrations increased significantly in FRD rats, those of insulin-receptor-substrate-
(IRS-) 1 and IRS-2 were reduced. PIO coadministration prevented FRD eﬀects on LEP, PAI-1, and IRS-2 (fully) and IRS-1
(partially) mRNAs in AAT. Conclusion. PPARγ would play a relevant role in the development of the FRD-induced metabolic-
endocrine dysfunction.
1. Introduction
The annual per capita consumption of fructose has drastically
risen in the USA in recent decades [1], and some authors
consider that this increased consumption could actively
contribute to the development of the current epidemics of
obesity, type 2 diabetes, andmetabolic syndrome (MS) [2, 3].
Several studies have also demonstrated that administration
of a fructose-rich diet (FRD) to normal rats induces the
development of features characteristic of the human MS
phenotype [4–7]. For these reasons, US Dietary Guidelines
recommend limiting calorie intake (which includes both
added sugar and solid fat) to 13% of energy requirement [8].
Although the precise mechanism whereby FRD induces
the features of MS is still controversial, it has been suggested
that an increased rate of oxidative stress (OS) is actively
involved [9–13]. In this regard, we have previously reported
increased OS in abdominal adipose tissue (AAT) [14] and
impaired adipoinsular axis function [14, 15] in normal rats
fed an FRD for 3 weeks.
Despite that the metabolism of fructose by pancreatic β
cells is poor or null [16, 17], fructose can potentiate insulin
secretion induced by physiological concentrations of glucose
[18]. Because fructose aﬀects diﬀerent cells of the digestive
tract [19], liver [20], and adipose tissue [21, 22], it can
indirectly modulate pancreatic β-cell function through the
release of metabolites and hormones/adipokines by those
tissues. The facts that the intake of an FRD increases serum
triglyceride and insulin levels and impairs glucose tolerance
supports this assumption [14, 15]. All these alterations could
be consequences of the enhancement in the OS rate [14]
and/or the impairment of tissue insulin sensitivity induced
by fructose [6, 23–25].
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On account that PPAR-γ plays an important role in
the control of tissue-insulin sensitivity, we currently studied
the involvement of those receptors in the FRD-induced
AAT endocrine dysfunction. For this aim, we investigated
the eﬀect of simultaneous administration of FRD and
pioglitazone (PIO), an eﬀective PPAR-γ agonist [26, 27]
on (a) circulating concentrations of metabolic, endocrine,
and OS markers, (b) morphometric characteristics of AAT
adipocytes, (c) in vitro leptin release by isolated AAT
adipocytes, and (d) expression of adipokines and of intracel-
lular insulin mediators (insulin-receptor-substrate- (IRS-) 1
and IRS-2) in the AAT.
2. Materials andMethods
2.1. Animals and Experimental Design. Normal adult male
Wistar rats (180–200 g body weight) were kept in a
temperature-controlled environment (23◦C) on a fixed 12-
hour light/dark cycle and fed ad libitum for one week
(stabilization period) with a standard commercial diet (rat
chow, Ganave, Argentina). Thereafter, rats were randomly
divided into four groups (30 animals each) and fed ad
libitum for 3 weeks with (i) commercial standard chow and
tap water (control diet group; CD), (ii) CD diet plus 10%
fructose (w/v; Carlo Erba Reagents, Italy) in drinking water
(FRD group), (iii) CD diet plus daily injection (i.p.) of PIO
(0.25mg/Kg BW; Lab. Phoenix, Argentina) [28] (CD-PIO),
and (iv) FRD diet plus PIO (FRD-PIO). Rats from both CD
and FRD groups also received daily i.p. injections of 300 μL
of sterile vehicle only. This study protocol complies with
international regulations concerning the ethical use and care
of animals.
2.2. Blood Measurements. Nonfasting animals were killed
(between 08:30 and 09:00 h), trunk blood was collected into
EDTA-coated tubes, rapidly centrifuged (4◦C at 3,000 rpm),
and plasma samples were immediately analysed or stored at
−20◦C. Commercial assay kits were used to measure plasma
levels of glucose (Bio System Lab., Argentina), triglyceride
(TG) (Wiener Lab., Argentina), and nonesterified fatty acids
(NEFA; Randox Laboratories Ltd., UK). Plasma insulin
concentration was determined by radioimmunoassay (RIA)
[29] and lipid peroxidation by measuring thiobarbituric
acid reactive substances (TBARS) [14]. Amount of TBARS
formed was calculated by the extinction coeﬃcient for the
malonaldehyde-TBA complex of 1.56 × 105 (mol/L)−1 cm−1
and expressed as pmol of TBARS per mg of plasma protein
(measured with the Bio-Rad Protein Assay kit; Bio-Rad Lab,
RC, USA). Leptin (LEP) concentration in plasma and in the
incubation medium samples as well as in AAT extracts was
measured by a validated specific RIA (standard curve 0.04–
15 ng/mL) [30]. The coeﬃcients of variation (CV) intra- and
interassay of insulin and LEP RIAs were 3–7% and 5–9%,
respectively. Since plasminogen activator inhibitor-1 (PAI-1)
is another keymarker of AAT dysfunction [15], its circulating
levels were also measured using a commercial ELISA kit
(American Diagnostica, Inc., CT, USA, IMUCLONE Cat. no.
601; standard curve 1–20 ng/mL, CVs intra- and interassay
were 0.5–2% and 4–9%, resp.).
2.3. Histological Studies. AAT pads were removed and imme-
diately fixed in 4% paraformaldehyde (in 0.2M phosphate
buﬀer), at 4◦C for a maximum of 3 days. Tissues were
then washed with 0.01MPBS, immersed in 70% ethanol,
and thereafter embedded in paraﬃn. Sections of 4 μm were
taken from diﬀerent levels of the blocks and stained with
haematoxylin eosin. Quantitative morphometric analysis
was performed using a Jenamed 2 Carl Zeiss light micro-
scope, a RGB CCD Sony camera, and OPTIMAS software
(Bioscan Incorporated, Edmons, WA, USA) (40x objective).
For each AAT sample, 1 section and 3 levels were selected (n =
4/5 animals per group). Systematic random sampling was
used to select 10 fields for each section and aminimumof 100
cells per group were counted. We then measured adipocyte
diameter, whereas cell volume was calculated by the formula
4/3π·r3 [31].
2.4. Isolation and Incubation of Adipocytes from AAT.
Adipocytes were isolated from preweighed AAT by a minor
modification of the Rodbell procedure [29]. Briefly, fat
pads were transferred into sterile plastic tubes containing
Krebs-Ringer-MOPS medium with 1% BSA (Sigma Chem.
CO, MO, USA) (w/v), 25mg/L streptomycin, and 15mg/L
potassium penicillin G and supplemented with 1mg/mL
collagenase type 1 (Sigma) (pH 7.4; 4mL/g AAT). Tubes were
incubated at 37◦C with gentle shaking for 40min; thereafter,
the fat suspension was filtered through a nylon cloth
and centrifuged (30 sec at 400 rpm) at room temperature.
Infranatants were aspirated and adipocytes washed with
10mL of fresh sterile Krebs-Ringer-MOPS-BSAmedium and
centrifuged (3 times) as described above. Cells were then
diluted with 3-4mL of sterile Dulbecco’s Modified Eagle’s
Medium (Sigma) (supplemented with 1%BSA, 1% FCS (v/v)
and antibiotics (see above), pH 7.4 (incubation medium))
and counted. Cell samples were then diluted with incubation
medium to yield ∼200,000 adipocytes/900mL distributed in
15mL conical tubes and incubated for 45min at 37◦C, in a
95%O2-5% CO2 atmosphere without (basal) or with insulin
(0.1–10 nM, Novo Nordisk Pharma AG, Switzerland) [29].
At the end of the incubation period, aliquots of media were
carefully separated and kept frozen (−20◦C) to measure LEP
concentration. For this analysis, we used samples taken from
5 diﬀerent experiments performed in 6 replicates.
2.5. AAT RNA Isolation and Real-Time Quantitative PCR.
Total RNA was isolated from AAT pads of all experi-
mental groups by a modification of the single-step, acid
guanidinium isothiocyanate-phenol-chloroform extraction
method (Trizol; Invitrogen, Life Tech., USA; cat. no. 15596-
026) [32]. The yield and quality of extracted RNA were
assessed by 260/280 nm optical density ratios and elec-
trophoresis in denaturing conditions on 2% agarose gel.
One microgram of total RNA was reverse-transcripted
using random primers (250 ng) and Superscript III Rnase
H-Reverse Transcriptase (200U/μL Invitrogen, Life Tech,
USA; cat no. 18989-093). For quantitative real-time PCR,
the following primers were applied: β-actin (ACTB) (R)
50-ACCCTCATAGATGGGCACAG-30, (F) 50-AGCCAT-
GTACGTAGCCATCC-30 (115 bp) (GenBank accession
PPAR Research 3
Table 1: Initial and final (on third week after diet/treatment) rat body weight (BW) and 21-day average of energy intake.
CD CD-PIO FRD FRD-PIO
Initial BW (g) 192.44± 2.41 195.33± 6.37 189.78± 3.42 190.95± 3.18
Final BW (g) 301.83± 11.82 277.72± 9.31∗ 296.14± 6.44 270.78± 9.55∗+
Energy intake(cal/day/100 g BW) 25.91± 0.98 24.53± 2.56 28.82± 2.12 29.11± 2.83
Values are means ± SEM, n = 7/8 rats per group.
∗P < 0.05 versus CD values; +P < 0.05 versus FRD values.
Table 2: Circulating levels of several markers of the adipoinsular axis function and TBARS.
CD CD-PIO FRD FRD-PIO
Glucose (mM) 7.16 ± 0.27 6.78 ± 0.25 8.27± 0.23∗ 7.11± 0.21+
Insulin (ng/mL) 0.75 ± 0.03 0.71 ± 0.08 1.13± 0.05∗ 0.89± 0.13+
Triglyceride (g/L) 1.11 ± 0.09 1.01 ± 0.06 1.74± 0.12∗ 1.19± 0.09+
NEFA (mM) 0.59 ± 0.04 0.56 ± 0.03 0.77± 0.05∗ 0.48± 0.05+
LEP (ng/mL) 4.77 ± 0.35 3.31 ± 0.25 6.67± 0.57∗ 4.88± 0.55+
PAI-1 (ng/mL) 1.59 ± 0.22 2.12 ± 0.37 3.72± 0.51∗ 2.01± 0.42+
TBARS (pmol/mg) 69.02 ± 5.09 79.15 ± 3.31 88.85± 3.13∗ 64.88± 9.89+
Values are means ± SEM, n = 7/8 rats per group.
∗P < 0.05 versus CD values; +P < 0.05 versus FRD values.
number: NM 031144); LEP (R) 50-CTCAGCATTCAG-
GGCTAAGG-30, (F) 50-GAGACCTCCTCCATCTGCTG-
30 (192 bp) (GenBank accession number: NM 013076);
PAI-1 (R) 50-TCTCCAGGGGCCCTCTGAGGT-30, (F)
50-TGCCCCTCTCCGCCATCACC-30 (141 bp) (GBAN:
NW 047370); IRS-1 (R) 50-ACGGTTTCAGAGCAGAGG-
AA-30, (F) 50-TGTGCCAAGCAACAAGAAAG-30 (176 bp)
(GenBank accession number: NM 012969); IRS-2 (R) 50-
CCAGGGATGAAGCAGGACTA-30, (F) 50-CTACCCACT-
GAGCCCAAGAG-30 (151 bp) (GenBank accession num-
ber: AF087674); glucose transporter (GLUT)-4 (R) 50-
TGGACGCTCTCTTTCCAACT-30, (F) 50-GCTTCTGTT-
GCCCTTCTGTC-30 (166 bp) (GenBank accession number:
NM 012751).
Two μL of the reverse transcription mix were amplified
by the QuantiTect Syber Green PCR kit (Qiagen Inc., CA,
USA, cat. No. 204143, 0.5mM of each specific primer and
the Light Cycler Detection System, MJ Mini Opticon, Bio-
Rad, CA, USA). PCR eﬃciency was ∼1. Threshold cycles
(Ct) were measured in separate tubes and in duplicate. The
identity and purity of the amplified product were checked by
electrophoresis on agarose minigels, and the melting curve
was analysed at the end of amplification. Diﬀerences in cycle
threshold (Ct) were calculated in every sample for each gene
of interest as follows: Ct gene of interest and Ct reporter gene.
ACTB, whose mRNA levels did not diﬀer between control
and test groups, was used as reporter gene. Relative changes
in the expression level of one specific gene (ΔΔCt) were
calculated as ΔCt of the test group minus ΔCt of the control
group, then expressed as 2-ΔΔCt.
2.6. Statistical Analysis. Data were analysed by ANOVA
(two factors: diet and treatment), followed by post hoc
comparisons with Fisher’s test [33]. The nonparametric
Mann-Whitney test was applied to analyse data on adipose
tissue mRNA concentration [33]. Results are expressed as
mean ± SEM, and diﬀerences were considered significant
when P values were below 0.05.
3. Results
3.1. Body Weight and Calorie Intake. All experimental groups
had comparable body weights both at the beginning and
after the 3-week study period; thus, they also showed a
comparable increase in body weight (Table 1). Although
animals receiving PIO have also increased significantly their
body weight, their final values were significantly lower than
those of PIO-untreated rats (Table 1).
Comparable amounts of daily energy intake were
recorded over the 3-week experimental period in animals of
all groups regardless of treatment or diet (Table 1).
3.2. Circulating Biomarker Levels
3.2.1. Metabolites and TBARS. Rats fed with the FRD had
significantly (P < 0.05 versus CD rats) higher plasma
concentration of glucose, TG, NEFA, and TBARS (Table 2),
thus indicating abnormal carbohydrate and lipidmetabolism
as well as an increased OS. PIO administration to FRD rats
eﬀectively prevented the development of all these abnormal
changes (Table 2).
3.2.2. Hormone and Adipokine Levels. Plasma levels of
insulin and of all adipokinesmeasured increased significantly
(P < 0.05 versus CD rats) in the FRD rats (Table 2),
thus suggesting an adipose tissue and β-cell dysfunc-
tion. Coadministration of PIO to these rats significantly
4 PPAR Research
Table 3: Abdominal adipose tissue (AAT) characteristics in male rats fed either a CD or FRD combined or not with PIO treatment.
CD CD-PIO FRD FRD-PIO
AAT mass (g) 1.87± 0.21 1.95± 0.28 2.48± 0.17∗ 2.11± 0.21
Cell number (×106) per g AAT 2.94± 0.05 3.05± 0.29 2.08± 0.11∗ 2.59± 0.21+
AAT cell diameter (μm) 50.11± 0.79 43.88± 1.01∗ 57.37± 0.69∗ 42.12± 1.78∗+
AAT cell volume (μm3 × 103) 66.28± 2.89 47.32± 3.88∗ 92.51± 3.22∗ 44.11± 5.21∗+
Values are means ± SEM, n = 7/8 rats per group.
∗P < 0.05 versus CD values; +P < 0.05 versus FRD values.
(a) (b)
(c) (d)
Figure 1: Representative fields of AAT from CD (a), FRD (b), CD-PIO (c), and FRD-PIO (d) rats stained with hematoxylin eosin (scale bar:
50 μm; magnification: ×400).
(P < 0.05) decreased plasma levels of insulin, leptin, and PAI-
1 (Table 2).
3.3. AAT Mass and Adipocyte Characteristics. AAT mass was
slightly but significantly (P < 0.05) larger in FRD than in
CD rats (Table 3), a diﬀerence that was not longer observed
in PIO-treated rats, regardless of the diet. A significantly
(P < 0.05) smaller number of adipocytes was obtained by
collagenase digestion of AAT pads from FRD than from
CD rats (Table 3); this diﬀerence was not found in rats
treated with PIO, regardless of the diet (Table 3). However,
the number of adipocytes obtained from AAT pads was
significantly (P < 0.05) lower in FRD than in FRD-PIO group
(Table 3).
These data closely correlate with changes observed in
the size/volume of adipocytes (Figures 1(a)–1(d)). In fact,
the AAT adipocytes of FRD rats were significantly (P <
0.05) larger (diameter and volume) than adipocytes of CD
PPAR Research 5
LE
P
 (
n
g/
m
L 
of
 m
ed
iu
m
)
0
0.2
0.4
0
0.1 1 10
Insulin (nM)
∗
∗∗
CD
FRD
∗
∗+ ∗+
+
+
(a)
LE
P
 (
n
g/
m
L 
of
 m
ed
iu
m
)
0
0.2
0.4
0 0.1 1 10
Insulin (nM)
CD-PIO
FRD-PIO
∗
∗∗
∗
∗ ∗
(b)
Figure 2: Eﬀects of increasing concentrations of insulin on leptin release by adipocytes isolated from AAT of untreated CD and FRD rats
(a) and from CD-PIO and FRD-PIO rats (b). Means ± SEM (n = 5 diﬀerent experiments, with 6 replicates per condition). ∗P < 0.05 versus
respective 0 nM insulin; ∗∗P < 0.05 versus 0.1 nM insulin; +P < 0.05 versus CD or CD-PIO in similar condition.
rats (Table 3). Additionally, adipocytes from PIO-treated rats
were smaller than those of untreated rats regardless of the
diet administered (Table 3).
3.4. FRD-Induced Changes in AAT Leptin Content and Release:
PIO Eﬀect. The LEP content of AAT in FRD rats was
significantly higher (P < 0.05) than in CD animals: 9.08 ±
2.06 versus 4.13 ± 0.23 ng/ng DNA (n = 7/8 rats per group).
Although PIO treatment did not modify LEP content in CD
rats (3.35 ± 0.96 ng/ng DNA; n = 7 rats), it fully prevented
the increase induced by FRD (5.33 ± 1.12 ng/ng DNA; P <
0.05; n = 8 rats).
Adipocytes isolated from AAT of all experimental groups
and incubated either without (baseline) or with increasing
concentrations of insulin (0.1 to 10 nM; Figure 2) released
leptin in a concentration-dependent fashion. This release was
significantly higher in adipocytes isolated from FRD rats in
any condition tested (Figure 2(a)). However, the threshold
for insulin-induced leptin release in adipocytes from these
rats shifted to the right (decreased insulin sensitivity), that
is, a significant increase in leptin release (P < 0.05 versus
baseline) started at an insulin concentration 10 times greater
(1 versus 0.1 nM) in adipocytes from FRD rats than in those
isolated from CD rats (Figure 2(b)).
PIO coadministration did not aﬀect leptin release in CD
rats but it cut down its release in adipocytes from FRD rats
to values comparable to those recorded in adipocytes from
CD rats (Figure 2(b)), thus removing the diﬀerence between
groups. However, PIO failed to fully correct impaired insulin
sensitivity in FRD adipocytes (Figures 2(a) and 2(b)).
3.5. Adipokines, IRS-1, and IRS-2 Gene Expression in AAT.
The mRNA content of LEP and PAI-1 in AAT was signifi-
cantly (P < 0.05) higher in FRD than in CD rats (Figures 3(a)
and 3(b), resp.). Although PIO administration to CD rats did
not aﬀect LEP and PAI-1 gene expression (versus CD rats), it
abolished the enhanced expression of both genes in FRD rats
(Figures 3(a) and 3(b), resp.). AAT IRS-1 and IRS-2 mRNA
expression was significantly lower (P < 0.05) in FRD than in
CD rats (Figure 4, both panels). Interestingly, PIO treatment
partially and fully (P < 0.05) abolished the detrimental
eﬀect of FRD on AAT IRS-1 and IR-2 mRNA concentration,
respectively (Figures 4(a) and 4(b)). Neither treatment- nor
diet-dependent changes in AAT GLUT-4 mRNA expression
were found (data not shown).
4. Discussion
Our current data support the reliability of the FRD rat
model for its capacity to induce multiple metabolic and
endocrine dysfunctions [14, 15]. Many of these changes are
similar to those present in the human phenotype of MS
[4–7, 34] which makes this animal model a useful tool to
either study the production mechanism of such changes
6 PPAR Research
0
0.5
1
1.5
2
A
A
T
 L
E
P
 m
R
N
A
 (
A
U
)
CD FRDCD-PIO FRD-PIO
∗
+
(a)
0
0.5
1
1.5
2
2.5
CD FRD
A
A
T
 P
A
I-
1 
m
R
N
A
 (
A
U
)
∗
CD-PIO FRD-PIO
+
(b)
Figure 3: LEP (a) and PAI-1 (b) mRNA abundance in AAT pads from CD and FRD rats without or with PIO treatment. Data (expressed
in arbitrary units: AU) were normalized to the levels of ACTB, and then presented as relative to values obtained in fat pads from CD rats.
Means ± SEM (n = 5/6 pads per group). ∗P < 0.05 versus CD; +P < 0.05 versus FRD.
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Figure 4: AAT IRS-1 (a) and IRS-2 (b) mRNA expression in pads from CD and FRD rats without or with PIO treatment. Data (expressed
in arbitrary units: AU) were normalized to the levels of ACTB, and then presented as relative to values obtained in fat pads from CD rats.
Means ± SEM (n = 5/6 pads per group). ∗P < 0.05 versus CD; +P < 0.05 versus FRD.
or to test the eﬀectiveness of diﬀerent treatment strategies.
In fact, these animals portrait high plasma concentrations
of metabolites and OS markers (glucose, NEFA, TG, and
TBARS), insulin, and adipokines (LEP and PAI-1); these
abnormally high levels of biomarkers support those reported
in diﬀerent studies [4–7, 14, 15, 35] and demonstrate the
existence of several metabolic and tissue dysfunctions such
as (a) impaired insulin sensitivity, (b) abnormal glucose and
lipid metabolism, and (c) AAT dysfunction. Nonetheless,
the present study selectively focused attention on the AAT
dysfunction.
Since no significant diﬀerences were recorded in energy
intake among the experimental groups, the lower final
body weight of animals receiving PIO might be ascribed
to a diﬀerent utilization of metabolic substrates induced by
this treatment. The changes described above in circulating
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metabolic and endocrine markers as well as those analysed
below lend support to this assumption.
AAT from FRD rats underwent significant changes in
its mass (enlarged), adipocyte morphology (increased size),
adipokine content (high leptin concentration), gene expres-
sion (enhanced LEP and PAI-1 mRNA abundance), and
intracellular insulin mediators (decreased expression of IRS-
1 and IRS-2 genes). Their adipocytes also displayed in vitro
higher baseline and insulin-stimulated leptin release together
with a decreased sensitivity to this stimulus. Altogether these
changes indicate that FRD induces serious and multiple
adipocyte dysfunctions whose development was eﬀectively
prevented by coadministration of PIO.
The decrease in plasma insulin levels recorded in FRD
rats treated with PIO indicates that the overall insulin sen-
sitivity was significantly improved; however, the decreased
sensitivity of the adipocytes from these animals to insulin
stimulation was not fully corrected by this treatment. This
latter eﬀect could be mechanistically associated to the fact
that PIO partially corrected the impaired IRS-1 signalling
in AAT; thus, these data suggest that AAT is not the main
component of the overall insulin resistance in our rat
model and that other mechanism/s rather than changes in
insulin sensitivity could be involved in the FRD-induced AAT
dysfunction.
Because leptin is an active regulator of insulin activity,
its high production (plasma levels and adipocyte release)
could play a key role in the mechanism whereby FRD induces
the alterations described above. In fact, high leptin levels
aﬀect insulin binding to its receptor [36] and reduce IRS-
1/2 intracellular mediators downstream [37, 38], thereby
potentiating and perpetuating overall insulin resistance.
These data could explain the relationship between the high
serum levels of leptin and reduced IRS-1/2 intracellular
mediators, as well as the overall impaired insulin sensitivity
present in our FRD rats.
Regarding the potential role of PPAR-γ receptors in the
production mechanisms of the abnormalities induced by
FRD in AAT, PIO is an agonist of these receptors [26, 39–
41] that exerts multiple eﬀects on liver, muscle, and adipose
tissue function [26, 27, 39, 40], including their sensitivity
to insulin [27, 41]. In our case, its coadministration with
the FRD eﬀectively prevented the development of almost all
the alterations induced by this diet. Thus, it is tempting to
speculate that (a) PPAR-γ receptors could play a significant
role in the mechanism whereby FRD induces AAT metabolic
and endocrine dysfunctions (and probably in other tissues)
and (b) such role could be exerted, at least partly, by
improving insulin sensitivity.
As previously mentioned, however, we cannot discard
that other mechanisms are probably involved in the PIO-
preventive eﬀect recorded in this study. In this regard, FRD
intake induces metabolic and endocrine dysfunctions by
enhancing OS [14, 42], as we previously reported [14] and
currently confirmed. PPAR-γ agonists can decrease OS both
in vitro [43, 44] and in vivo [45] and also increase the
expression of catalase [46]. In our case, PIO coadministra-
tion significantly decreased the serum TBARS levels. Thus,
perhaps the first event triggered by the FRD is an increase
in OS rate that secondarily could impair insulin sensitivity,
being these two eﬀects responsible for the development of all
the abnormal changes associated to its administration. Our
current design, however, cannot completely define whether
these are concurrent or sequential eﬀects, one being primary
in relation to the other. Otherwise, thiazolidinediones could
also exert metabolic eﬀects through PPAR-γ-independent
mechanism [47–49], such as the eﬀective antagonism on
glucocorticoid receptor [50]. Consequently, PIO could dis-
play through this path an additional cooperative antidiabetic
eﬀect [50].
5. Conclusions
Our data firmly demonstrate that the multiple deleterious
eﬀects of FRD administration during 3 weeks upon the
AAT function in normal rats can be largely counteracted
by coadministration of pioglitazone. The PPAR-γ agonist
preventive eﬀect could be ascribed either to its action upon
tissue insulin sensitivity and/or its antioxidant eﬀect. The
present data strongly suggest that these receptors play an
active role in the mechanism whereby FRD exerts its dele-
terious eﬀect upon metabolic and endocrine AAT functions.
Nevertheless, the eﬀectiveness of PIO treatment on FRD-
elicited AAT dysfunction should not be solely ascribed to
its PPAR-γ agonistic property. Otherwise, it also suggests
that the development of new PPAR-γ agonists devoid of
undesirable side eﬀects of those currently available might be
a useful tool to neutralize the damaging eﬀect of excessive
fructose consumption.
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